within Pharmacolibrary.Drugs.ATC.L;

model L01DC03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.031,
    k12             = 58,
    k21             = 58
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01DC03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mitomycin is an antineoplastic antibiotic used primarily as a chemotherapeutic agent for the treatment of various cancers, including stomach, pancreas, breast, and bladder cancer. It works by inhibiting DNA synthesis in tumor cells. Mitomycin is approved for use in several countries and is typically administered intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult cancer patients following intravenous administration of mitomycin.</p><h4>References</h4><ol><li><p>van Ruth, S, et al., &amp; Zoetmulder, FA (2003). Pharmacokinetics of intraperitoneal mitomycin C. <i>Surgical oncology clinics of North America</i> 12(3) 771–780. DOI:<a href=\"https://doi.org/10.1016/s1055-3207(03)00031-0\">10.1016/s1055-3207(03)00031-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14567030/\">https://pubmed.ncbi.nlm.nih.gov/14567030</a></p></li><li><p>van Hazel, GA, &amp; Kovach, JS (1982). Pharmacokinetics of mitomycin C in rabbit and human. <i>Cancer chemotherapy and pharmacology</i> 8(2) 189–192. DOI:<a href=\"https://doi.org/10.1007/BF00255482\">10.1007/BF00255482</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6809356/\">https://pubmed.ncbi.nlm.nih.gov/6809356</a></p></li><li><p>Fang, YP, et al., &amp; Huang, YB (2018). Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics. <i>Drug design, development and therapy</i> 12 159–169. DOI:<a href=\"https://doi.org/10.2147/DDDT.S150201\">10.2147/DDDT.S150201</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29391780/\">https://pubmed.ncbi.nlm.nih.gov/29391780</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01DC03;
